Kura Oncology — Third Quarter 2026 Earnings Summary

Kura Oncology reported third-quarter 2026 net product revenue of $13.9 million for KOMZIFTI, representing a 53% sequential increase driven by a 30% rise in new patient starts. The company secured FDA alignment for a 40-patient monotherapy registrational study of darlifarnib in HRAS-mutant salivary gland cancer, with initiation targeted for the first half of 2027. Financially, Kura maintains a strong position with $492.1 million in cash and short-term investments, supported by a new strategic financing agreement with Oberland Capital providing up to $300 million in potential funding.